Fig. 1 | Scientific Reports

Fig. 1

From: Causal role of the pyrimidine deoxyribonucleoside degradation superpathway mediation in Guillain-Barré Syndrome via the HVEM on CD4 + and CD8 + T cells

Fig. 1

Diagrams illustrating associations examined in this study. (A) The total effect between superpathway of pyrimidine deoxyribonucleoside degradation and Guillain-Barré syndrome (GBS). c is the total effect using genetically predicted superpathway of pyrimidine deoxyribonucleoside degradation as exposure and GBS as outcome, d is the total effect using genetically predicted GBS as exposure and superpathway of pyrimidine deoxyribonucleoside degradation as outcome. (B) The total effect was decomposed into: (i) indirect effect using a two-step approach (where a is the total effect of superpathway of pyrimidine deoxyribonucleoside degradation on HVEM on CM CD4 + , HVEM on naive CD4 + , HVEM on CD45RA-CD4 + , HVEM on CM CD8br in the maturation stages of T cell, and b is the effect of HVEM on CM CD4 + , HVEM on naive CD4 + , HVEM on CD45RA-CD4 + , HVEM on CM CD8br in the maturation stages of T cell on GBS) and the product method (a x b) and (ii) direct effect (c’ – c – a x b). Proportion mediated was the indirect effect divided by the total effect. e is a causal relationship analysis process that uses 11 gut microbiota as exposure and superpathway of pyrimidine deoxyribonucleoside degradation as the result.

Back to article page